Capricor Therapeutics Inc (NASDAQ:CAPR) Receives Consensus Recommendation of “Buy” from Brokerages

Capricor Therapeutics Inc (NASDAQ:CAPR) has received a consensus rating of “Buy” from the six research firms that are covering the stock, MarketBeat reports. Six investment analysts have rated the stock with a buy recommendation. The average 12 month price target among brokerages that have covered the stock in the last year is $34.50.

A number of analysts recently issued reports on the company. HC Wainwright reissued a “buy” rating and set a $77.00 price objective on shares of Capricor Therapeutics in a report on Thursday, January 2nd. Maxim Group upped their target price on Capricor Therapeutics from $12.00 to $25.00 and gave the stock a “buy” rating in a research note on Wednesday, September 25th. Piper Sandler started coverage on Capricor Therapeutics in a research note on Monday, October 21st. They issued an “overweight” rating and a $35.00 target price on the stock. Cantor Fitzgerald upped their target price on Capricor Therapeutics from $25.00 to $30.00 and gave the stock an “overweight” rating in a research note on Thursday, November 14th. Finally, Oppenheimer restated an “outperform” rating and issued a $15.00 target price on shares of Capricor Therapeutics in a research note on Monday, September 23rd.

Capricor Therapeutics Stock Performance

Shares of CAPR opened at $13.70 on Monday. The stock’s 50-day simple moving average is $15.46 and its 200 day simple moving average is $11.60. The stock has a market capitalization of $622.94 million, a price-to-earnings ratio of -12.92 and a beta of 4.08. Capricor Therapeutics has a 52-week low of $3.52 and a 52-week high of $23.40.

Hedge Funds Weigh In On Capricor Therapeutics

Institutional investors have recently modified their holdings of the company. Renaissance Technologies LLC increased its position in shares of Capricor Therapeutics by 158.7% during the 2nd quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company’s stock valued at $656,000 after purchasing an additional 84,350 shares during the last quarter. Marshall Wace LLP bought a new position in shares of Capricor Therapeutics during the 2nd quarter valued at about $426,000. State Street Corp increased its position in shares of Capricor Therapeutics by 27.8% during the 3rd quarter. State Street Corp now owns 512,313 shares of the biotechnology company’s stock valued at $7,792,000 after purchasing an additional 111,291 shares during the last quarter. Point72 Asset Management L.P. purchased a new stake in Capricor Therapeutics during the 3rd quarter valued at about $3,806,000. Finally, The Manufacturers Life Insurance Company purchased a new stake in Capricor Therapeutics during the 3rd quarter valued at about $161,000. 21.68% of the stock is currently owned by institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.